

TECHNICAL DATA SHEET

In Vivo Ready™ Anti-Mouse CD274 (PD-L1, B7-H1)

Catalog Number: 40-1243

PRODUCT INFORMATION

Contents: In Vivo Ready™ Anti-Mouse CD274 (PD-L1, B7-H1)

Isotype: Rat IgG2b, kappa

Concentration: 2 mg/mL

Clone: 10F.9G2

Reactivity: Mouse

Formulation: 10 mM NaH₂PO₄, 150 mM NaCl, pH7.2

Endotoxin Level: Less than or equal to 0.01 EU/ug, as determined by the LaL assay

DESCRIPTION

The 10F.9G2 antibody is specific for mouse CD274, more commonly known as PD-L1 or B7-H1, which acts as a ligand for the T cell co-regulatory receptor PD-1 (CD279). This interaction modulates T cell antigen receptor (TCR) signaling and therefore T cell activation. PD-L1 binding to PD-1 expressed on CD4⁺ CD8⁻ thymocytes participates in the processes of clonal selection, elimination of autoreactive lymphocytes, and development of tolerance. PD-L1 may also bind PD-1 following the receptor's inducible expression on activated, mature T cells, where it has been proposed to limit T cell activation. PD-L1 is one of a group of "B7" ligands whose interactions with the CD28 receptor family, also including CTLA-4 (CD152), provide a balance of co-stimulatory /co-inhibitory signaling important in T cell activation, tolerance, and autoimmunity. The 10F.9G2 antibody may be used as a marker for PD-L1 expression on T and B cells, NK cells and on dendritic cells. It is also widely used for analysis of receptor-ligand interaction and function(s) in vitro and in vivo.

PREPARATION & STORAGE

This monoclonal antibody preparation was purified from tissue culture supernatant via affinity chromatography. For In Vivo Ready™ (IVR) products, each preparation is also evaluated for endotoxin levels using the LAL assay. It is recommended to store the product undiluted at 4°C. Do not freeze.

APPLICATION NOTES

This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications.

REFERENCES

Chen A, Ahlen G, Brenndorfer ED, Brass A, Holmstrom F, Chen M, Soderholm J, Milich DR, Frelin L, and Sallberg M. 2011. J. Immunol. 186:5107-5118. (in vivo depletion) Zhang L, Gajewski TF, and Kline J. 2009. Blood. 114:1545-1552. (in vivo blocking) Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking) Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, and Oldstone MBA. 2008. Proc. Natl. Acad. Sci. 105:20428-20433. (in vivo blocking) Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)

NOTE: Please choose the appropriate format for each application. Citations are provided as a convenience to you; please consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.